<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04577703</url>
  </required_header>
  <id_info>
    <org_study_id>PCD-DCT053-12-003</org_study_id>
    <nct_id>NCT04577703</nct_id>
  </id_info>
  <brief_title>First-In-Human Phase I Trial of Ningetinib ( CT053PTSA ) in the Patients With Advanced Solid Tumors</brief_title>
  <official_title>Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ningetinib (CT053PTSA) in Patients With Advanced Solid Tumors: A Phase I, Single-arm, Single-center, Open-label, Dose-escalation Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunshine Lake Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunshine Lake Pharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I, single-arm, single-center, open-label, dose-escalation Study evaluating&#xD;
      the safety and efficacy of CT053PTSA in patients with Advanced Solid Tumors&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a dose-escalation study. The primary purpose is to determine the dose limiting&#xD;
      toxicity (DLT), maximum tolerated dose (MTD) and recommend doses and regimen of CT053PTSA for&#xD;
      further studies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 8, 2014</start_date>
  <completion_date type="Actual">December 10, 2015</completion_date>
  <primary_completion_date type="Actual">December 10, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>Cycle 0 Day 1 to Cycle 1 Day 28</time_frame>
    <description>The maximum tolerated dose (MTD) of the CT053PTSA will be determined according to incidence of dose-limiting toxicity (DLT) assessed by NCI CTCAE v4.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of CT053PTSA_Cmax</measure>
    <time_frame>Cycle 0 Day 1 to Cycle 1 Day 28</time_frame>
    <description>To evaluate the Pharmacokinetics (PK) of CT053PTSA with Maximum observed plasma concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of CT053PTSA_Tmax</measure>
    <time_frame>Cycle 0 Day 1 to Cycle 1 Day 28</time_frame>
    <description>To evaluate the Pharmacokinetics (PK) of CT053PTSA with Time of maximum observed plasma concentration (Tmax).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of CT053PTSA_AUC</measure>
    <time_frame>Cycle 0 Day 1 to Cycle 1 Day 28</time_frame>
    <description>To evaluate the Pharmacokinetics (PK) of CT053PTSA with Area under the plasma concentration time curve (AUC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of CT053PTSA_ORR</measure>
    <time_frame>up to approximately 36 months</time_frame>
    <description>To assess overall response rate (ORR) for patients treated CT053PTSA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of CT053PTSA_DCR</measure>
    <time_frame>up to approximately 36 months</time_frame>
    <description>To assess disease control rate (DCR) for patients treated CT053PTSA.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>CT053PTSA (dose escalation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients were treated in 5 dose cohorts of 15 mg, 30 mg, 60 mg, 100 mg, and 150 mg QD capsules.&#xD;
Patients receive treatment with CT053PTSA once on Cycle 0 Day 1 following a 7-day treatment-free withdrawal period to observe the safety and pharmacokinetic of CT053PTSA.&#xD;
After that, Patients receive treatment with CT053PTSA per orally, beginning on Cycle 1 Day 1 for 28 day following a 7-day treatment-free withdrawal period to observe efficacy of CT053PTSA and determine to continue taking medicine or not. Each cycle had 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CT053PTSA</intervention_name>
    <description>CT053PTSA will be administered daily in fasting state</description>
    <arm_group_label>CT053PTSA (dose escalation)</arm_group_label>
    <other_name>Ningetinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - A. Subjects with advanced solid tumors confirmed by histologically or cytologically that&#xD;
        are refractory to current treatment or for which there is not a current standard of care B.&#xD;
        Toxicity recovered to NCI CTCAE v.4.0 Grade ≤1 from previous treatments (chemotherapy,&#xD;
        radiotherapy or surgery) C. ECOG performance status (PS) 0 or 1 D. Life expectancy of ≥ 12&#xD;
        weeks E. Adequate organ function&#xD;
&#xD;
          1. Hemoglobin &gt; 9 g/dL (SI Units: 90 g/L) without transfusion support or growth factors;&#xD;
             Platelet count ≥ 100 × 10^9/L; Absolute neutrophil count (ANC) ≥ 1.5 × 10^9/L without&#xD;
             growth factor support.&#xD;
&#xD;
          2. AST/SGOT and/or ALT/SGPT≤ 2.5 × upper limit of normal (ULN) or ≤ 5.0× ULN if liver&#xD;
             metastases are present; serum bilirubin ≤ 1.5×ULN&#xD;
&#xD;
          3. Serum creatinine ≤ 1.5×ULN&#xD;
&#xD;
          4. Blood potassium≥ 3.0 mmol/L; serum calcium≥2.0 mmol/L&#xD;
&#xD;
          5. Fasting serum triglyceride level≤5.7 mmol/L&#xD;
&#xD;
          6. Asymptomatic abnormal serum amylase≤1.5×ULN&#xD;
&#xD;
          7. Serum lipase≤ ULN&#xD;
&#xD;
          8. INR≤ 1.5×ULN；APTT≤ 1.5×ULN； PT ≤ 1.5×ULN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Chemotherapy, immunotherapy, radiotherapy, or major surgery within 4 weeks prior to&#xD;
             study treatment&#xD;
&#xD;
          2. Nitrosourea, anthracyclinea and mitomycin chemotherapy within 6 weeks prior to study&#xD;
             treatment&#xD;
&#xD;
          3. Had received live vaccine within 4 weeks prior to study treatment&#xD;
&#xD;
          4. Had received any investigational agent from other clinical study within 4 weeks prior&#xD;
             to study treatment or are currently participating in other clinical trials&#xD;
&#xD;
          5. Previous treatment with any other c-MET inhibitor or HGF inhibitor&#xD;
&#xD;
          6. Symptomatic, untreated or unstable central nervous system metastases&#xD;
&#xD;
          7. Spinal cord compression, carcinomatous meningitis or leptomeningeal diseaseonly&#xD;
             (patient are only permitted if treated, asymptomatic and stable for at least 4 weeks&#xD;
             prior to start of study treatment)&#xD;
&#xD;
          8. Patients with hypertension that can't be well controlled by drugs (systolic blood&#xD;
             pressure&gt; 140 mmHg or diastolic blood pressure&gt; 90 mmHg)&#xD;
&#xD;
          9. Doppler ultrasound evaluation：Left ventricular ejection fraction &lt; 50%&#xD;
&#xD;
         10. Grade ≥ 2 of arrhythmia (assessed by NCI CTCAE 4.0), or symptomatic bradycardia, or&#xD;
             male with QTCF &gt; 450 ms or female with QTCF &gt; 470 ms, or patients with a history of&#xD;
             torsion or congenital QT prolonged syndrome long QT syndrome&#xD;
&#xD;
         11. Certain factors that would preclude adequate absorption of CT053PTSA (eg. unable to&#xD;
             swallow, chronic diarrhea, intestinal obstruction)&#xD;
&#xD;
         12. Significant hemoptysis within 2 months prior to enrollment, or a daily hemoptysis&#xD;
             volume is 2.5 ml or above&#xD;
&#xD;
         13. Patients with evidence of bleeding tendency, including the following cases:&#xD;
             gastrointestinal bleeding, hemorrhagic gastric ulcer, fecal occult blood ++ and above;&#xD;
             or melena or hematemesis within 2 months; or visceral bleeding that may occur&#xD;
             considered by investigator&#xD;
&#xD;
         14. History of immunodeficiency, or other acquired or congenital immunodeficiency, or&#xD;
             history of organ transplantation&#xD;
&#xD;
         15. Any disease of the following bellowed within 12 months prior to administration:&#xD;
             Myocardial infarction, severe angina, or unstable angina, coronary or peripheral&#xD;
             artery bypass graft, congestive heart failure, or cerebrovascular events (including&#xD;
             transient ischemic attack)&#xD;
&#xD;
         16. Pulmonary embolism within 6 months prior to administration&#xD;
&#xD;
         17. Active infection of hepatitis B, hepatitis C, or infection of HIV&#xD;
&#xD;
         18. Undergone a bone marrow or solid organ transplant.&#xD;
&#xD;
         19. Patients with severe retinopathy or exfoliation in the investigator's judgment&#xD;
&#xD;
         20. Patients need to be supplemented with stem cells before receiving large dose&#xD;
             chemotherapy (except for myeloma or lymphoma)&#xD;
&#xD;
         21. History of thyroid dysfunction, and the thyroid function cannot be maintained at the&#xD;
             normal range with drugs.&#xD;
&#xD;
         22. Anticoagulants, vitamin K antagonists, other anti-tumor drugs and drugs that prolong&#xD;
             the QT interval are not allowed.&#xD;
&#xD;
         23. Serious electrolyte imbalance in the investigator's judgment&#xD;
&#xD;
         24. Pregnant or lactating woman&#xD;
&#xD;
         25. Any other reason the investigator considers the patient is not suitable to participate&#xD;
             in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 16, 2020</study_first_submitted>
  <study_first_submitted_qc>September 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>September 30, 2020</last_update_submitted>
  <last_update_submitted_qc>September 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

